Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TELA Bio (TELA) EBT (2018 - 2025)

TELA Bio has reported EBT over the past 8 years, most recently at $30.3 million for Q4 2025.

  • Quarterly results put EBT at $30.3 million for Q4 2025, up 3.46% from a year ago — trailing twelve months through Dec 2025 was $556000.0 (down 9.59% YoY), and the annual figure for FY2025 was $556000.0, down 9.59%.
  • EBT for Q4 2025 was $30.3 million at TELA Bio, up from -$8.6 million in the prior quarter.
  • Over the last five years, EBT for TELA hit a ceiling of $30.3 million in Q4 2025 and a floor of -$13.6 million in Q4 2023.
  • Median EBT over the past 5 years was -$10.4 million (2022), compared with a mean of -$6.2 million.
  • Biggest five-year swings in EBT: soared 314.7% in 2024 and later tumbled 98.06% in 2025.
  • TELA Bio's EBT stood at -$8.6 million in 2021, then decreased by 23.75% to -$10.6 million in 2022, then dropped by 28.36% to -$13.6 million in 2023, then surged by 314.7% to $29.2 million in 2024, then rose by 3.46% to $30.3 million in 2025.
  • The last three reported values for EBT were $30.3 million (Q4 2025), -$8.6 million (Q3 2025), and -$9.9 million (Q2 2025) per Business Quant data.